天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

ChemicalBook--->CAS DataBase List--->104138-64-9

104138-64-9

104138-64-9 Structure

104138-64-9 Structure
IdentificationBack Directory
[Name]

Agalsidase Beta
[CAS]

104138-64-9
[Synonyms]

Agalsidase Beta
Research Grade Fabrazyme/Agalsidase Alfa (DHC19529)
Hazard InformationBack Directory
[Description]

Fabry's disease is a rare genetic glycolipid-storage disorder characterized by the deficiency of the lysosomal enzyme a-galactosidase A. This enzyme participates in the catabolism of the glycosphingolipid globotriaosylceramide (Gb3) by specifically cleaving its terminal s-linked galactose residue. Progressive accumulation of Gb3 and related glycosphingolipids in vascular endothelial lysosomes of the kidneys, heart, skin and brain leads to several chronic symptoms such as debilitating neuropathic pain and characteristic cutaneous lesions called angiokeratomas. As vital organs are affected with age, premature death usually occurs in the fourth or fifth decade of life due to renal, cardiac or cerebral complications. Agalsidase alfa is delivered to its lysosomal site of action via the recognition of its mannose-6-phosphate (M6P) residues by specific M6P receptors on the cell surface followed by endocytosis. In clinical trials, twice weekly intravenous infusions of agalsidase alfa over six months to one year have been found to be safe and effective in reversing the accumulation of microvascular endothelial deposits of globotriaosylceramide in the kidneys, heart and skin.
[Originator]

Transkaryotic Therapies (US)
[Uses]

Treatment of Fabry Disease.
[Definition]

ChEBI: Eliglustat tartrate is a tartrate that is the hemitartrate salt of eliglustat. A ceramide glucosyltransferase inhibitor used (as its tartrate salt) for treatment of Gaucher's disease. It has a role as an EC 2.4.1.80 (ceramide glucosyltransferase) inhibitor. It contains an eliglustat(1+).
[Brand name]

Replagal (Transkaryotic Therapies).
[Clinical Use]

Treatment of Fabry disease. Only to be prescribed by specialist centres.
[Drug interactions]

Potentially hazardous interactions with other drugs
Fabrazyme should not be administered with chloroquine, amiodarone, benoquin or gentamicin due to a theoretical risk of inhibition of intra-cellular α-galactosidase activity.
[Metabolism]

Metabolic degradation pathway similar to other proteins.
104138-64-9 suppliers list
Company Name: Beijing HuaMeiHuLiBiological Chemical   
Tel: 010-56205725
Website: www.huabeibiochem.com
Company Name: Wuhan Chemstan Biotechnology Co., Ltd.  
Tel: 027-65317797 15926423062
Website: http://www.chemstan.com/
Company Name: Biolab Reagents  
Tel: 027-65279366 18108604862
Website: www.biolabreagent.com/
Company Name: Atagenix Laboratories  
Tel: 027-87008169 17762441161
Website: www.atagenix.cn
Tags:104138-64-9 Related Product Information